Site Map
Pages
-
About
- Contact us
- CQDM
- Equity, Diversity and Inclusion (EDI)
- Governance
-
Team
- Alexandre Morizot
- Alysia Melnychuk
- Annie Bernier
- Catherine-Alexandra Grégoire
- Fanny Guimont-Desrochers
- Jeanne Ouellet-Ayotte
- Jesse Paterson
- Julia Serafino
- Koffi Locoh
- Kristin Davis
- Lina Chaya
- Marina Luginina
- Mathieu Paquette
- Rebeca Baca-Diaz
- Samar Khoury
- Sandra Constantin
- Sandrine Campeau
- Simon Fournier
- Véronique Dugas
- Xavier Linker
- Who We Are ?
-
Achievement
-
Funded Projects
- 89Zr/225Ac-labeled antibody radioconjugates as theranostic against EGFR-positive colorectal cancer – a clinical trial enabling study
- A 150-plex affinity proteomics platform for high throughput and high content phenotypic cell screening
- A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases
- A brain-specific approach to RNA therapeutics: developing a novel protein delivery strategy for the central nervous system
- A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders
- A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines
- A novel immunotherapy based on genetically modified hematopoietic stem cells as a new hope for treating glioblastoma, an aggressive cancerous tumor of the brain
- A novel phage-based screening technology for antiviral
- A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer
- A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers
- A Screening Technology to Improve the Discovery of Function-Modifying Antibodies Against Membrane Protein Targets
- A Zebrafish-Based Platform for Nuclear Receptor Drug Screening and Pathway Discovery in Metabolic Disease and Cancer
- Accelerate the development of highly targeted, less toxic cancer therapies using AI
- Acting on membrane protein-protein interactions: Mammalian Membrane Two Hybrid (MaMTH) as an Innovative Technology for Drug Discovery Against Protein- Protein Interactions
- Alzheimer’s Disease Mouse Model Characterization: Correlation Between MRI and ex vivo Immunohistochemistry
- Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia
- Artificial intelligence-powered platform for analyzing the success of clinical trials and interpreting risk factors
- Artificial Liver for Safer and more Effective Drugs: Three-Dimensional Liver Tissue Models for High-Throughput Screening of the Efficacy and Hepatotoxicity of Drugs
- Automated Zebrafish High Throughput Drug Screening Platform: An Automated Zebrafish High Throughput Technology to Accelerate in vivo Screening of Small Molecules in Disease Models
- Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections
- Biomarkers Discovery in Diabetes: New Biomarkers for Measurement of Early Stage Diabetes Disease and for Prediction of Response to Therapy
- Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets
- Catecholamine-Regulated Protein 40 (CRP40) as a New Candidate Biomarker for Early Diagnosis of Parkinson’s Disease
- Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform
- Computational and machine learning approaches to improve design and screening of peptides in drug discovery
- Conditional oncology therapies and companion diagnostics: an AI-optimized approach for enhanced clinical success
- Connecting cellular signalling data with behavioural and clinical outcomes for 5-HT receptor ligands
- Cycloinformatics: A Platform to Rapidly Produce Macrocyclic New Chemical Entities to inhibit Protein- Protein Interactions
- Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases
- Defining the Rules That Will Enhance the Cell Permeability and Oral Bioavailability of Macrocycles
- Design and Characterization of Feldan Shuttle Peptides and Derivatives as Pulmonary Delivery Agent
- Designing synthetic extracellular matrices to support neurodegenerative disease modeling
- Detection of Molecular Interaction Field Similarities for the Rational Drug Design of Multi-Functional Inhibitors
- Develop and evaluate antisense oligonucleotide (ASO) delivery using Feldan Shuttle technology for the treatment of respiratory lung diseases
- Developing an evidence-based approach to diagnose and treat adults with a history of concussion
- Developing marine worm M101 hemoglobin extract for cancer therapy
- Developing New Alzheimer’s Therapeutics Using a Novel Carrier That Can Cross the Blood-Brain Barrier
- Developing open access protein degradation tools for drug discovery
- Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population
- Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders
- Development of a high throughput bioprinted 3D human tumor microenvironment assay that recreates immune “hot” and “cold” tumors
- Development of a new class of oral and highly potent non-statin LDL-cholesterol lowering therapeutics for patients at high cardiovascular risk
- Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas
- Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance
- Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine
- Development of immunotherapy for bladder cancer using IMV’s drug delivery platform
- Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers
- Development of novel biologic inhibitors of Semaphorin3A for the treatment of retinal vascular diseases.
- Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia
- Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias
- Development of pharmacological correctors for Alpha-1 antitrypsin deficiency (ATD) using VIPER
- Dimer Interfering peptides (DIPs): A novel platform for targeting the immunosuppressive functions of prototypic galectins
- Discovery of analgesic drugs targeting the acid-sensing ion channel family
- Elatus: Chronically implantable unit-scale microelectrode array neuromodulation technology
- Engineering Endogenous Vesicles as a Drug Delivery Platform to Inhibit Gene Expression Using microRNAs and Silencing RNAs
- Establishing a world-class biophysics platform that will enable and accelerate the discovery of leads for launching drug-discovery programs
- Establishment of an Expert Center for Rare Complement Mediated Diseases
- Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs
- Facilitating Anti-Cancer Drug Discovery with Selective Inhibitors to Modulate the Protein Ubiquitination Process
- First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
- FlAsH-Walk Mapping: An Innovative Step-by-Step Approach to G Protein-Coupled Receptor Conformation Cartography
- Fragment-Based Lead Discovery: Bridging the Gap Between Screening and Hit-to-Lead Medchem using NMR Affinity Ranking
- Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
- Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
- Identification of T Cell Receptor Somatic Mutations Driving Autoimmunity in Human Rheumatoid Arthritis
- Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias
- In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)
- In-vivo CAR-T therapy for glioblastoma by novel non-viral gene editing system
- In-vivo Solid Phase Microextraction Integrated with Mass Spectrometry Platform for Untargeted and Targeted Investigation of the Brain
- Inducible human pluripotent stem cells to better understand and treat Parkinson’s disease and ALS
- Inducible Mouse Models to Accelerate Drug Development for Parkinson’s Disease and Other Synucleinopathies
- Innervated, Vascularised and Immunocompetent Human Skin Model for Screening the Sensitization Potential of Chemicals
- Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma
- Innovative Optical Imaging and Bio-Simulation Platforms to Accelerate Central Nervous System Drug Discovery
- Integrating Tumour-Microenvironment Biomarkers to Improve Diagnostic and Facilitate Targeted Breast Cancer Therapy
- Intelligent digital pathology applied to the diagnosis of neuroendocrine tumors of the pancreas
- Intracellular delivery of antibodies and peptides using a peptide-based technology
- IPPER, the Integrated Platform for the Pharmacology of the Endoplasmic Reticulum and protein trafficking diseases
- Leveraging genomics and proteomics to identify novel biomarkers and drug targets for diabetic kidney disease
- Live Cell Imaging System for Protein-Protein Interactions: Multiplexing Fluorescence Lifetime Imaging: a rapid HCS system to study protein-protein interactions in live cells
- Macrocyclic peptides as the next-generation immuno-oncology therapeutics
- Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites
- Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets
- Monitoring Conformational Changes in Channel Proteins: A Novel Approach for Rapid Screening of Ion Channel Hits
- Monitoring the Signaling Pathways of G Protein Coupled Receptors in Living Animals to Accelerate Drug Discovery
- Multimodal digital biomarkers for the identification of companion diagnostic tools in cardiovascular diseases.
- New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects
- New Processes Mimicking the Spray drying technique for the Preparation of Thermally Stable Vaccines
- Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders
- Novatek VR: Autonomous Artificial Intelligence (AI) Driven Cognitive Screening Tests and Virtual Reality (VR) Rehabilitation
- Novel biological agents in the treatment of amyotrophic lateral sclerosis based on progranulin/granulin structure
- Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer
- Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets
- Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
- Novel Non-Invasive Laser-Assisted Intraocular Drug Delivery System for an Efficient and Selective Gene Transfer Therapy
- Novel p53-activiting MDM2 inhibitor oncology platform therapy
- Optimizing KBTBD4-CoREST1 acting compounds for tissue rejuvenation
- Optimizing the monitoring of patients with DLBCL
- Personalized Medicine 2.0: Integrated Functional and Genomic Profiling to Determine Optimum Combination Therapy for Cancer Patients
- Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment
- Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs
- Platform to target small-molecule therapeutics to bone – Novel prodrugs to selectively deliver therapeutics to bone
- Pre-clinical design of a novel targeted and personalized treatment against sortilin-positive triple negative breast cancers
- Preclinical development of a Pseudomonas aeruginosa vaccine
- Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment
- PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension
- Quantification of Her2 expression in breast cancer tumors using plasmonic nanoparticles as protein markers
- QUO2 MRI: Quantitative Measurement of Metabolic and Vascular Anomalies in the Brain of Alzheimer’s Disease Patients
- RecyTag technology for extended half-lives of small biologics
- Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers
- Selectomics to monitor and predict the emergence of resistance to antibiotics by using the human microbiome
- ShARP: Screenable Assays for RNA-Binding Proteins Involved in Brain Disorders
- Synthetic lethality platform to discover, test and validate new therapeutic treatment options for cancer
- Targeting the Right Cells: Human MiniPromoters for Restricted Gene Expression in Specific Cells of the Eyes
- Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine
- The application of 3D models to assess the role of microglia in neurodegenerative disorders
- The Encapsulated Liver Tissue as a treatment for acute liver failure: proof-of-concept efficacy and safety in large animals using liver organoids composed of primary cells
- The eye: a window to the brain – Detection of Alzheimer’s Disease in the Prodromal Stage from Non-Invasive Hyperspectral Retinal Images
- Topic nanovectors for targeted gene therapy of cutaneous psoriasis
- Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers
- Treating acute decompensation of urea cycle disorders by transient implantation of an Encapsulated Liver Tissue
- Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.
- TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)
- Unlocking a class of challenging drug targets using a next generation screening and lead development platform technology
- Using Patient’s Blood to Develop a Sensory Neuron-Based Platform to Treat Chemotherapy-Induced Peripheral Neuropathy
- Validation of KQ-791 in combination immunotherapies cancer models
- VIPER, the lentiviral IPPER platform for drug discovery in trafficking diseases. IPPER-accelerated development of pharmacological correctors for cystic fibrosis
- VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles
- YCharOS Inc. (Antibody Characterization through Open Science): A platform enabling neuroscience target validation
- Zebrafish High Throughput Screening Platforms for Nuclear Receptor-Related Drug Discovery and Pathway Elucidation
- Structuring Initiatives
- Success Story
-
Funded Projects
- Call for Research Projects on the Brain
- Careers
- Cookie policy
- Funding R&D
- Members and Partners
-
News and Events
- $1.5M to accelerate drug discovery within the Quebec-Ontario Life Sciences Corrido
- $50 million to support biotech companies
- 15th of CQDM.
- 2021 Sweet Pharma Day Winner is HDAX Therapeutics
- 2023 Sweet Biopharma Day Winner is Epitopea!
- 2024 OBIO Investment Summit
- 2nd Annual Gordon Shore Prize - Postdoctoral Internships in the Biopharmaceutical Industry
- 2nd Annual Gordon Shore Prize – Call for Proposal to Private Companies
- 2nd edition of Connect-Pharma : Pitch day.
- 3rd edition of Connect-Pharma : Pitch day.
- 4,000 subscribers to our LinkedIn page
- 48Hour Discovery and Merck initiate drug discovery project - Project funded through CQDM Quantum Leap program
- 4th edition of Sweet Biopharma Day – Call for entries now open
- A 150-plex affinity proteomics platform for high throughput and high content phenotypic cell screening
- A 5th competition for the Quebec/France Program
- A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases
- A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders
- A genetic test to predict diabetic nephropathy in Type 2 diabetes patients
- A new partnership between CQDM, the Canadian Cancer Society, the Cole Foundation and Oncopole to support pediatric cancer research
- A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines
- A novel phage-based screening technology for antiviral
- A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer
- A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers
- A project funded by CQDM redefines the treatment of cancer
- A research project originally funded by CQDM and Brain Canada leads to a new partnership between the Centre for Drug Research and Development (CDRD), the Montreal Neurological Institute and Hospital at McGill University (MNI), and Merck
- A Screening Technology to Improve the Discovery of Function-Modifying Antibodies Against Membrane Protein Targets
- A Zebrafish-Based Platform for Nuclear Receptor Drug Screening and Pathway Discovery in Metabolic Disease and Cancer
- Accelerating the transition from idea to market - Submission of the RSRI brief
- Access funding for your RD projects with the support of conscience and CQDM
- Acting on membrane protein-protein interactions: Mammalian Membrane Two Hybrid (MaMTH) as an Innovative Technology for Drug Discovery Against Protein- Protein Interactions
- ADRIQ 2022 Award – Warmest congratulations to Steven LaPlante of INRS and NMX Research and Solutions, winners of the Industrial Sectoral Research Group Award (RSRI) presented by CQDM!
- ADRIQ* 2021 AWARD – CQDM congratulates Feldan Therapeutics for receiving the 2021 ADRIQ RSRI (regroupements sectoriels de recherche industrielle) award.
- AI and drug development
- Ali Tehrani appointed on CQDM’s Board of Directors
- Alzheimer’s Disease Mouse Model Characterization: Correlation Between MRI and ex vivo Immunohistochemistry
- Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics
- Amgen becomes a new member of CQDM to further the development of cutting-edge drug discovery
- Announcement - The therapeutic potential of a marine oxygen carrier
- Announcement - World Cancer Day
- Announcement – Development of a New Diagnostic Technique for Targeted Treatment of Breast Cancer
- Announcement – Innovative Treatments for Diabetic Kidney Disease
- Announcement – Rare Disease Day
- Announcement – Research project promoting cellular rejuvenation
- Announcement of a new funding from the Government of Canada
- Announcement of an investment of close to $8 million dollars in biopharmaceutical research in Québec
- Appointment of Véronique Dugas as President and Chief Executive Officer of CQDM
- Appointments to the CQDM Board of Directors.
- Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia
- Artificial Liver for Safer and more Effective Drugs: Three-Dimensional Liver Tissue Models for High-Throughput Screening of the Efficacy and Hepatotoxicity of Drugs
- Automated Zebrafish High Throughput Drug Screening Platform: An Automated Zebrafish High Throughput Technology to Accelerate in vivo Screening of Small Molecules in Disease Models
- Axelys and the sector-based industrial research clusters are joining forces to boost innovation in Quebec for the benefit of research centers, businesses and society.
- Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections
- Become a CQDM Member.
- Bernard Massie and Cameron Black appointed to CQDM’s Scientific Advisory Board
- Biomarkers Discovery in Diabetes: New Biomarkers for Measurement of Early Stage Diabetes Disease and for Prediction of Response to Therapy
- BIOQuébec, QCDD, NEOMED Institute, Montréal InVivo and Rx&D call on political parties to spell out their intentions and priorities for the life science sector
- Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets
- Call for Applications – Hippocrates Awards 2025 Now Open
- Call for Applications for the Gordon Shore Prize - Internships for new graduates
- Call for collaborative research projects on precision care in oncology
- Call for Ideas in Radiopharmaceuticals
- Call for Ideas: AI-assisted protein design
- Call for ideas: driving innovation in personalized medicine through translational research and collaboration.
- Call for Ideas: Innovations in RNA therapeutics and modalities
- Call for Ideas: Innovations in Targeting Moieties for Precision Therapeutics
- Call for Proposal to Private Companies - Post-Diploma Internships Co-Funded through the Gordon Shore Prize
- Call of ideas : Driving innovation in personalized medicine through translational research and collaboration
- Canadian Cancer Society and CQDM announce a partnership of $5 million for breast cancer research in Quebec
- Catecholamine-Regulated Protein 40 (CRP40) as a New Candidate Biomarker for Early Diagnosis of Parkinson’s Disease
- Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform
- Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D
- Collaborative R&D – a Catalyst of Innovation for Biopharmaceutical Companies
- Communicating Life Sciences to the Public: Winners of “Tweete tes neurones!” challenge pitch in
- COMMUNICATIONS AND MARKETING COORDINATOR
- Competition results 2008-2009 (letter of intent)
- Computational and machine learning approaches to improve design and screening of peptides in drug discovery
- Congrats Sandra!
- Congratulations Alexandre Morizot.
- Congratulations Sandrine Campeau
- Congratulations to AmacaThera on its upcoming collaboration with a leading global pharmaceutical company!
- Congratulations to Glycovax Pharma for two major advances in the field of vaccines
- Congratulations to Synucure Therapeutics on securing $2.8M in funding!
- Congratulations to Variational AI on their collaboration with Merck!
- Congratulations Université Laval
- Connect-Bio : Collaborations to Propel Innovation in Neuroscience
- Connect-BIO: biomarkers and next-generation diagnostic tools
- Connect-BIO: New Opportunities Brought by Artificial Intelligence in the Development of Advanced Therapies
- Connect-BIO: Reinventing Preclinical Research – Approaches to Reduce Animal Use
- Contribution from the MEI ($3.3M) allows CQDM to support 5 biopharmaceutical research projects ($15.5M)
- CQDM 2014 Activity Report: A year of partnerships
- CQDM 5 years already and many achievements!
- CQDM acknowledges the success of the Forum Québécois des Sciences de la Vie which was organized by the government of Quebec
- CQDM and a group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec
- CQDM and Brain Canada Inject $1 M in Top BC Biotech Firm AbCellera to Advance Discovery Platform for Next-Generation Antibody Therapeutics
- CQDM and Brain Canada invest over $5.4M to drive neuroscience innovation in Canada
- CQDM and Brain Canada support the development of innovative therapeutic solutions for mental health disorders with Diamond Therapeutics
- CQDM and Defence Therapeutics fund the development of a new cancer vaccine platform
- CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Supportive Platform Enabling the Development of RNA-based Immunotherapies
- CQDM and Esphera SynBio Announce New Project to Advance Next Generation mRNA Vaccine Development, supported by the CQDM Quantum Leap program
- CQDM and Génome Québec joins to launch le Défi « Tweete tes neurones »
- CQDM and NanoGene Therapeutics Fund the Development of a Treatment for Psoriasis
- CQDM and Novatek International are funding the validation of a new therapeutic solution to treat mild cognitive impairment remotely
- CQDM and OCE co-fund a promising research collaboration in neuroscience
- CQDM and Oncopole are proud to announce the funding of a theranostic project, a pioneering approach set to transform cancer diagnosis and treatment
- CQDM and Sanofi Canada partner to accelerate drug discovery
- CQDM and SPM Therapeutics fund a study carried out by Professor Boilard at the CHU de Québec-Université Laval to develop a treatment for systemic lupus erythematosus
- CQDM and the Canadian Cancer Society commend Theratechnologies and UQAM for their success in developing a new therapy against the most aggressive form of breast cancer
- CQDM and the Massachusetts Life Sciences Center announce a new international partnership program
- CQDM and the Sorintellis Group fund the development of an AI-powered platform to mitigate clinical trial risks
- CQDM and the Stem Cell Network focus on regenerative medicine to revolutionize therapeutic approach to urea cycle disorders
- CQDM and YCharOS Inc. fund the development of an antibody characterization platform to facilitate R&D and propel the development of new drugs
- CQDM announces a new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec
- CQDM announces funding to develop a test to predict disease progression in patients infected with COVID-19
- CQDM Announces New Member to its Precompetitive Research Consortium to Accelerate Drug Discovery: Janssen Inc.
- CQDM Announces the Arrival of Carl Baillargeon in its Team
- CQDM announces the creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies
- CQDM announces the creation of training programs to meet the needs of the RNA therapeutics industry
- CQDM appoints Brian Underdown as the Chair of its Scientific Advisory Board (SAB) and nominates 3 new SAB members
- CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval ...
- CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology
- CQDM Congratulates Perceiv AI, DalCor Pharmaceuticals, and Dr. Tardif for Winning the 2024 ADRIQ RSRI Innovation Award
- CQDM congratulates recipients of the second call for projects from the Fonds d'accélération des collaborations en santé (FACS)
- CQDM Congratulates Theratechnologies and Professor Borhane Annabi from UQAM.
- CQDM funds a collaborative research project between the RI-MUHC and Divocco AI to develop an artificial intelligence-driven technology that improves regional anesthesia
- CQDM Funds a Project Aiming to Elucidate the Effets of Psilocybin on Neuronal Circuits in Order to Treat Depression
- CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation
- CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation
- CQDM Funds Four Projects to Transform Innovation Into Promising Medical Solutions
- CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
- CQDM funds two collaborative research projects to unlock the potential of RNA therapies
- CQDM grants $1.15 M in funding to Professor Yves St-Pierre’s team to develop a revolutionary immunotherapy against breast cancer
- CQDM initiates a unique collaboration with Merck, Pfizer and Biospective on Alzheimer’s disease
- CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology
- CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies
- CQDM is proud to announce a new collaboration / broadcast / communication partnership with OBIO.
- CQDM is proud to announce an investment of $1.5 M in two collaborative projects from the Québec/Ontario corridor
- CQDM is proud to be part of Optina Diagnostics' success
- CQDM is proud to contribute to the success of Medicago and its partners, winners of the 2020 RSRI Innovation Award from ADRIQ
- CQDM is proud to present a new series of events: Connect-Pharma
- CQDM is proud to welcome our new Network Member: RNA Technologies and Therapeutics!
- CQDM is recruiting! Interested in a summer Internship position in Administration and Accounting? Apply now!
- CQDM joins forces with Neurasic Therapeutics, CSVS and the Louise and Alan Edwards Foundation to fund the development of a non-opioid analgesic
- CQDM nominates John Delaney and Jennifer Hamilton as Scientific Advisory Board members
- CQDM nominates Kuldeep Neote as Scientific Advisory Board member
- CQDM partners with D2R to enhance collaborations among researchers and industry in RNA research
- CQDM partners with GlycoNet to support innovative Glycomics research in Canada
- CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor
- CQDM portfolio company Mesentech secures new capital to bring lead product to clinical phase
- CQDM present at NeuroSphere
- CQDM receives funding of $ 11.7 M from the Federal Government
- CQDM receives the Innovation Price during the "Fête Champêtre 2010" of the Fondation Armand-Frappier
- CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet
- CQDM SynergiQc program now includes an additional section on breast cancer, in collaboration with the Canadian Cancer Society
- CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University
- CQDM to fund an international collaboration between Traffick Therapeutics, McGill University and the Lead Discovery Center
- CQDM to support a $1.1 M R&D project for Immune Biosolutions’ next-generation of anti-cancer treatment
- CQDM welcomes 3 new ''Network'' Members.
- CQDM Welcomes Daiichi Sankyo, Ono Pharmaceutical, and Otsuka Pharmaceutical as Newest Members of Its Consortium, Strengthening Its Ability to Connect Canada’s Biopharmaceutical Ecosystem with Global Pharmaceutical Leaders
- CQDM Welcomes Eli Lilly Canada, A Leading Innovative Pharmaceutical Company, to Support the Explore Program
- CQDM welcomes its new member "Network" VVector Bio!
- CQDM welcomes Novartis as a new contributing member to the Explore Program
- CQDM welcomes the update of the Quebec Life Sciences Strategy
- CQDM welcomes two additional Pharma members, Boehringer Ingelheim and GlaxoSmithKline Inc.
- CQDM welcomes two new pharma members to its biopharmaceutical research consortium
- CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium
- CQDM will be in Quebec City on October 10 to present its financing programs
- CQDM will partner with Feldan Therapeutics to support a $1.2M project, to improve a novel intra-cellular delivery technology
- CQDM will receive a grant from the BL-NCE to research better ways of developing and testing drugs that treat central nervous system diseases
- CQDM, Brain Canada and industry partners join forces to address unmet medical needs in the treatment of brain disorders
- CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the creation of a prize of excellence for graduate students in cancer research in memory of Professor Gordon Shore
- CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the two laureates of the 2019 Gordon Shore Prize
- CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases
- CQDM, HBHL, Corbin Therapeutics and Brain Canada award $1.5 M to McGill Prof. Philippe Gros
- CQDM, IVADO, and three Quebec-based companies invest $2M to accelerate the development of highly targeted, less toxic cancer therapies using AI
- CQDM, IVADO, and two Quebec-based companies join forces to accelerate the diagnosis of pancreatic neuroendocrine tumors using artificial intelligence
- CQDM, IVADO, and Two Quebec-Based Companies Join Forces to Advance AI-Driven Oncology Therapies and Companion Tests
- CQDM, MEDTEQ+ and Montréal InVivo partner with IVADO to promote digital health innovation
- CQDM, the CCS and Theratechnologies grant $1.7M to UQAM in breast cancer research
- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
- CQDM's 2015 Activity Report: A toolbox of success
- Creation of a global hub for RNA-based therapies in Quebec
- Cycloinformatics: A Platform to Rapidly Produce Macrocyclic New Chemical Entities to inhibit Protein- Protein Interactions
- Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases
- Défi Tweete tes neurones! - Optimum Vice President and general manager, Isabelle Perras, agrees to act as president of the jury
- Defining the Rules That Will Enhance the Cell Permeability and Oral Bioavailability of Macrocycles
- Design and Characterization of Feldan Shuttle Peptides and Derivatives as Pulmonary Delivery Agent
- Detection of Molecular Interaction Field Similarities for the Rational Drug Design of Multi-Functional Inhibitors
- Developing New Alzheimer’s Therapeutics Using a Novel Carrier That Can Cross the Blood-Brain Barrier
- Developing open access protein degradation tools for drug discovery
- Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population
- Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders
- Development of a high throughput bioprinted 3D human tumor microenvironment assay that recreates immune “hot” and “cold” tumors
- Development of a machine learning-based in-process quality monitoring technology for plants during vaccine manufacturing
- Development of a new class of oral and highly potent non-statin LDL-cholesterol lowering therapeutics for patients at high cardiovascular risk
- Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas
- Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance
- Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine
- Development of immunotherapy for bladder cancer using IMV’s drug delivery platform
- Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers
- Development of novel biologic inhibitors of Semaphorin3A for the treatment of retinal vascular diseases.
- Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia
- Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias
- Development of pharmacological correctors for Alpha-1 antitrypsin deficiency (ATD) using VIPER
- Diane Gosselin appointed President and Chief Executive Officer of CQDM
- Diane Gosselin Honoured by BIOTECanada for Outstanding Leadership in Health Innovation
- Dimer Interference: A novel Approach to Develop Galectin-7-Specific Inhibitors to treat Triple-Negative Breast Cancer
- Discovery of analgesic drugs targeting the acid-sensing ion channel family
- Domain Therapeutics, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology
- Drive innovation and performance by integrating equity, diversity, and inclusion
- Drug-enabling technology innovations get boost through OCE-CQDM Life Sciences R&D challenge
- Effervescence Panel with Conscience
- Encycle Therapeutics Launches Ground-Breaking Chemistry Platform
- Encycle Therapeutics working with major pharmaceutical companies to design rules for drugs meant to be swallowed
- Engineering Endogenous Vesicles as a Drug Delivery Platform to Inhibit Gene Expression Using microRNAs and Silencing RNAs
- Establishing a world-class biophysics platform that will enable and accelerate the discovery of leads for launching drug-discovery programs
- Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs
- Facilitating Anti-Cancer Drug Discovery with Selective Inhibitors to Modulate the Protein Ubiquitination Process
- First research project to be funded under the Canada/Germany Program
- First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
- FlAsH-Walk Mapping: An Innovative Step-by-Step Approach to G Protein-Coupled Receptor Conformation Cartography
- Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences
- Fragment-Based Lead Discovery: Bridging the Gap Between Screening and Hit-to-Lead Medchem using NMR Affinity Ranking
- Funding activities carried out in companies that are part of collaborative R&D Projects in Artificial Intelligence
- Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
- Germany and Canada join forces to enhance biopharmaceutical R&D internationally
- GlycoNet and CQDM collaborate to boost drug discovery and develop new health solutions for Canadians
- Glycovax Pharma, the National Research Council of Canada and the Université de Montréal, join forces to develop an innovative vaccine against the bacterium Pseudomonas aeruginosa (Pa), made possible through CQDM’s financial support
- GRANTS MANAGEMENT AND COMPLIANCE COORDINATOR
- Health Innovation: Investing Now to Face the Crises of Tomorrow
- Honoring Brian Underdown,: A Remarkable Career Dedicated to Innovation in Life Sciences
- Hope on the horizon for hard-to-treat breast cancers
- Identification of T Cell Receptor Somatic Mutations Driving Autoimmunity in Human Rheumatoid Arthritis
- Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias
- IMV and CRCHU de Québec-U Laval Collaboration Awarded a CQDM Grant to Develop First-in-class Dual Target T cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
- In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)
- In-vivo Solid Phase Microextraction Integrated with Mass Spectrometry Platform for Untargeted and Targeted Investigation of the Brain
- Inducible human pluripotent stem cells to better understand and treat Parkinson’s disease and ALS
- Inducible Mouse Models to Accelerate Drug Development for Parkinson’s Disease and Other Synucleinopathies
- Industrial research clusters congratulate new Minister of the Economy and Innovation
- Information Webinars – RNA Innovation for Businesses Program
- Innervated, Vascularised and Immunocompetent Human Skin Model for Screening the Sensitization Potential of Chemicals
- Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma
- Innovative Optical Imaging and Bio-Simulation Platforms to Accelerate Central Nervous System Drug Discovery
- Integrating Functional and Genomic Profiling for Optimal Combination Therapies for Cancer Patients
- Integrating Tumour-Microenvironment Biomarkers to Improve Diagnostic and Facilitate Targeted Breast Cancer Therapy
- Intracellular delivery of antibodies and peptides using a peptide-based technology
- IPPER, the Integrated Platform for the Pharmacology of the Endoplasmic Reticulum and protein trafficking diseases
- JOB OFFER - ADMINISTRATIVE ASSISTANT
- JOB OFFER - DIRECTOR SCIENTIFIC AFFAIRS
- JOB OFFER - SENIOR DIRECTOR ACCOUNTING AND FINANCE
- Julie Martineau appointed as Senior Director, Communications and Corporate Development of CQDM
- Launch of Merck Digital Sciences Studio (MDSS) in Montréal
- Launch of the CHU Sainte-Justine Centre d'expertise sur les maladies rares médiées par le complément
- Life sciences and health technologies should be the focus of Quebec’s next research and innovation policy
- Live Cell Imaging System for Protein-Protein Interactions: Multiplexing Fluorescence Lifetime Imaging: a rapid HCS system to study protein-protein interactions in live cells
- Lyonbiopôle, CQDM and Alsace BioValley organize the first joint networking event in Lyon to encourage the emergence of French-Quebec projects.
- Macrocyclic peptides as the next-generation immuno-oncology therapeutics
- Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites
- Make a difference! Job Opportunity: controller
- Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets
- Mario Chevrette appointed Vice President, Scientific Affairs of CQDM
- McGill, industry, CQDM and Brain Canada collaborate for drug discovery
- Merck Canada Invests $5 Million in Quebec Consortium for Drug Discovery to Support Biopharmaceutical Research
- Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in Life Sciences
- Merck Canada reaffirms its commitment to CQDM with $3M in funding to support biopharmaceutical innovation.
- Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation
- Michel Goldman appointed member of CQDM’s Board of Directors
- Monitoring Conformational Changes in Channel Proteins: A Novel Approach for Rapid Screening of Ion Channel Hits
- Monitoring the Signaling Pathways of G Protein Coupled Receptors in Living Animals to Accelerate Drug Discovery
- Multimodal digital biomarkers for the identification of companion diagnostic tools in cardiovascular diseases.
- Neomabs Biotechnologies, a company dedicated to developing new immunotherapies for cancer treatment launches in Montreal
- Neuro-CERVO Alliance partners with Simmunome, a Montreal-based artificial intelligence company
- New appointments to CQDM’s Board of Directors and Scientific Advisory Board
- New call for proposals under the Fonds d’accélération des collaborations en santé
- New Funding opportunity for Company-driven RNA Innovation | AReNA
- New funding opportunity for research on the brain!
- New funding opportunity for RNA therapies!
- New funding opportunity for your brain research!
- New funding opportunity for your regenerative research projects
- New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects
- New hire Jeanne Ouellet-Ayotte, Marketing & Communication Coordinator
- New hire Xavier Linker, new Director of Strategic Initiatives
- New hire, Kristin Davis, Project manager
- New hire,Lina Chaya, Administration Coordinator
- New leadership at CQDM
- New Member Joins CQDM’s Board of Directors
- New Network Member: Simmunome
- New partnership with ADRIQ.
- New partnership with Axelys.
- New partnership with Centech.
- New partnership with IVADO.
- New partnership with the Canada Foundation for Innovation via its Research Facilities Navigator.
- New Processes Mimicking the Spray drying technique for the Preparation of Thermally Stable Vaccines
- NEW PROGRAM: SYNERGIQC
- Newly hired, Koffi Loch, Chief accountant
- Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders
- Nouveau partenariat avec BIOQuébec.
- Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer
- Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets
- Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
- Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
- Novel Non-Invasive Laser-Assisted Intraocular Drug Delivery System for an Efficient and Selective Gene Transfer Therapy
- Novel p53-activiting MDM2 inhibitor oncology platform therapy
- nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery
- OCE and OBI are partnering with CQDM to the tune of 3 million dollars in innovative inter-provincial drug discovery programs.
- Opportunity of Biopharma Networking during the “Connect-Bio: Médecine personnalisée” event in 22 days.
- Optimizing the monitoring of patients with DLBCL
- Our first event Connect-Café
- Outside the box in neuroscience: CQDM and Brain Canada partner to fund breakthrough technologies to accelerate drug discovery
- Parkinson's disease: a first research collaboration between CQDM and Massachusetts
- PARTENAR-IA - * New * Grants for IA research projects applied to the biopharmaceutical sector
- Partnership agreement between CQDM and Alsace BioValley
- Patrick Wier and Jorge Puente appointed to CQDM’s Board of Directors
- Personalized medicine: CQDM and CIHR fund two promising research collaborations aligning academic and industrial research
- Personalized medicine: CQDM partners with CIHR to accelerate drug discovery across Canada
- Pfizer Canada renews its support to CQDM with a $550,000 contribution
- Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment
- Philip Tagari Appointed to CQDM’s Board of Directors
- Philippe Walker appointed Member of the Scientific Advisory Board of CQDM
- Philippe Walker is appointed chairman of CQDM’s Strategic Orientation Committee
- Photo-album of our event on November 26th, 2008
- Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs
- Platform to target small-molecule therapeutics to bone – Novel prodrugs to selectively deliver therapeutics to bone
- Postponed deadline to submit a SynergiQc project
- Pre-budget Consultations: 3 proposals from CQDM to boost Quebec's economy
- Pre-clinical design of a novel targeted and personalized treatment against Sortilin-positive triple negative breast cancers
- Pre-launch of a new call for proposals in June 2020: discover the latest updates!
- Preclinical assessment of aspartyl protease inhibitors as an antifungal therapeutic strategy
- Predict lung cancer risk.
- Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors.
- Project funded through CQDM will explore potential of Fusion Genomics’ ONETest™ to improve diagnosis of respiratory tract infections
- PROJECT MANAGER
- Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment
- Proud to announce Veronique is now chief of operations COO at CQDM
- Public/Private Partnerships and New Models to Stimulate Innovation: Examples from Quebec and Massachusetts
- PulmoBind: A Biomarker for Diagnosing Pulmonary Hypertension
- PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension
- Quantum Leap - Program Opened
- Quebec announces an investment of $9 Million for CQDM
- Québec Launches AReNA to Become a Global Leader in RNA Therapies
- Québec Research and Innovation Investment Strategy 2022-2027
- QUO2 MRI: Quantitative Measurement of Metabolic and Vascular Anomalies in the Brain of Alzheimer’s Disease Patients
- RecyTag technology for extended half-lives of small biologics
- Rémi Quirion joins the CQDM Board
- Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers
- Research project
- Richard Fajzel appointed new Chairman of CQDM’s Board of Directors
- SAVE THE DATE / Bio+ech Connec+ event taking place on Wednesday March 16th
- Scientific days of the CRCHUM.
- Selectomics to monitor and predict the emergence of resistance to antibiotics by using the human microbiome
- SEVEN EXCEPTIONAL GRADUATES HONORED BY THE SCHOOL
- SEVEN GRADUATES WHO MAKE ESG UQAM PROUD
- ShARP: Screenable Assays for RNA-Binding Proteins Involved in Brain Disorders
- Six new drug discovery acceleration projects supported by CQDM and Ontario Centres of Excellence showcase continued success of Quebec-Ontario Life Sciences Corridor
- Subscribe to our newsletters
- Success of a preclinical study against breast cancer.
- Supporting innovation is essential to our prosperity
- Sweet Biopharma Day’s 3rd Edition | Québec, Canada Call for startup proposals, now open
- Sweet pharma day
- SynergiQc-International: New funding opportunity for public-private biopharmaceutical research
- Synthetic lethality platform to discover, test and validate new therapeutic treatment options for cancer
- Targeting the Right Cells: Human MiniPromoters for Restricted Gene Expression in Specific Cells of the Eyes
- Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine
- The 10th anniversary of CQDM.
- The 4th edition of the innovative partnership forum organized by the CQDM and Montréal InVivo was a huge success
- The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research
- The Canadian Cancer Society, the Quebec Breast Cancer Foundation and CQDM join forces to fight breast cancer
- The CCS, CQDM and biotech companies will invest nearly $10M to support 3 breast cancer research projects
- The CQDM and Univalor have announced a collaboration agreement
- The CQDM has joined forces with the RSRI to send a strong message in the face of economic and commercial uncertainties: it is more urgent than ever to take action!
- The CQDM joins Genome Québec and the Ontario Genomics Institute for a partnering event in Toronto
- The CQDM launches its first call for proposals
- The Encapsulated Liver Tissue as a treatment for acute liver failure: proof-of-concept efficacy and safety in large animals using liver organoids composed of primary cells
- The eye: a window to the brain – Detection of Alzheimer’s Disease in the Prodromal Stage from Non-Invasive Hyperspectral Retinal Images
- The first CQDM funded project is a remarkable success – Thanks to CQDM funding, Medicago announces an important investment in Québec
- The French BIO-clusters Lyonbiopole and Alsace BioValley and CQDM join forces to foster R&D collaboration and emergence of France-Quebec projects
- The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala
- Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers
- Three new appointments to CQDM
- To see and hear...souvenir video of our 15th anniversary
- Topic nanovectors for targeted gene therapy of cutaneous psoriasis
- Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers
- Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.
- TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)
- Unlocking a class of challenging drug targets using a next generation screening and lead development platform technology
- Unprecedented mobilization of Quebec's research and innovation ecosystem against COVID-19
- Using Patient’s Blood to Develop a Sensory Neuron-Based Platform to Treat Chemotherapy-Induced Peripheral Neuropathy
- Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors
- Validation of KQ-791 in combination immunotherapies cancer models
- VIPER, the lentiviral IPPER platform for drug discovery in trafficking diseases. IPPER-accelerated development of pharmacological correctors for cystic fibrosis
- VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles
- Wallonia (Belgium) and Canada join forces in a new international initiative to improve biopharmaceutical R&D
- We are hiring! Manager – Communications & events - Apply now!
- We are hiring! Project Manager - Apply now!
- We are looking for the winning formula: administrative coordinator position
- We are looking for the winning formula: Communications and Marketing Coordinator
- We are looking for the winning formula: job offer! ACCOUNTING TECHNICIAN
- We are looking for the winning formula: job offer! ADMINISTRATIVE ASSISTANT
- We are looking for the winning formula: job offer! CHIEF ACCOUNTANT
- We are looking for the winning formula: job offer! FINANCIAL CONTROLLER
- We are looking for the winning formula: job offer! Project manager
- We are looking for the winning formula: job offer! SENIOR BUSINESS DEVELOPMENT POSITION, PHARMACEUTICAL PROGRAMS
- We are RECRUITING for a Communication position: Director of Communications and Public Relations - CQDM (Deadline to apply: January 27th)
- We are RECRUITING: General Director for Early Stage Clinical Trial
- We are RECRUITING! Interested in a Controller position? Apply now!
- We are RECRUITING! Interested in a Controller position? Apply now!
- We need your precious collaboration
- Welcome Annie Bernier.
- Welcome Aren!
- Welcome Catherine-Alexandra.
- Welcome Dorothy!
- Welcome to Julia Serafino
- Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support
- Zebrafish High Throughput Screening Platforms for Nuclear Receptor-Related Drug Discovery and Pathway Elucidation
- Privacy Policy
- PROJECT MANAGER (1-YEAR CONTRACT)
- Terms of Use
- VICE-PRESIDENT, PARTNERSHIPS & BUSINESS DEVELOPMENT